New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
08:25 EDTBGMDBG Medicine regains compliance with NASDAQ listing rules
In an 8-K filing, BG Medicine said it received written notice on December 27 from the Listing Qualifications Department of The NASDAQ Stock Market LLC that the company has regained compliance with NASDAQ Listing Rule 5450(b)(2)(A) for continued listing on the NASDAQ Global Market and the matter of non-compliance identified in NASDAQ’s December 10 notice to the company is now closed. NASDAQ concluded that the company has regained compliance with the continued listing requirements because, for 10 consecutive business days, from December 11 to December 24, the company’s market value of listed securities was $50,000,000 or greater.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 31, 2015
08:45 EDTBGMDBG Medicine sees requiring additional capital in 'near future'
Paul Sohmer, CEO of BG Medicine, said: "FDA clearance of the first automated assay for galectin-3 represents a significant commercial milestone for BG Medicine. Our commercial strategy will increasingly rely on the success of our automated partners to commercialize automated testing for galectin-3. We anticipate that beginning in the second half of 2015 our growth in revenues will depend on the timing and extent to which our automated partners are successful in gaining adoption of their automated tests for galectin-3. Concurrently, we will continue to manage aggressively our operating expenses and cash burn. We also expect that we will require additional capital in the near future to continue our operations and grow our business."
07:18 EDTBGMDBG Medicine files Premarket Notification with FDA for BGM Galectin-3 Test
Subscribe for More Information
07:11 EDTBGMDBG Medicine reports Q4 EPS (4c), one estimate (5c)
Reports Q4 revenue $554,000, one estimate $800,000.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use